A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Hemoglobin changes
No
United States: Food and Drug Administration
AMAG-FER-IDA-301
NCT01114139
June 2010
October 2012
Name | Location |
---|---|
AMAG Pharmaceuticals, Inc. | Lexington, Massachusetts 02421 |